DuPont Nutrition & Health and Lonza Specialty Ingredients announce an agreement under which the leading biotechnology and specialty ingredient company Lonza will manufacture and supply CARE4U™ 2’-FL – a human milk oligosaccharide (HMOs). This strategic manufacturing collaboration reinforces market confidence in the supply and premium quality of this specialty ingredient.
DuPont Nutrition & Health is a world leader in microbial technology, health and nutrition, and the development of HMOs is part of a larger microbiome investment strategy for DuPont and central to this is developing scalable production methods.
“By engaging strategically with Lonza, DuPont will be able to accelerate commercialization and offer high-quality HMOs to customers and prospects. The collaboration with Lonza will play a key role in DuPont’s business growth strategy by focusing on providing high-quality consumer health and wellness products,” said John Rea, Global Business Unit Leader, Cultures, Probiotics, Food Protection, HMO & Fibers, DuPont Nutrition & Health.
Lonza is a leading integrated solutions provider to the global consumer health care, pharmaceutical, nutrition, and personal care industries with a comprehensive portfolio of proprietary nutritional ingredients, innovative formulation and delivery technologies and a strong platform in biotechnology. Lonza has been manufacturing high-quality products since 1897 and now has 50 major manufacturing sites that span the globe.
Partnering with DuPont, Lonza will apply its leading science and biotechnology expertise in consumer health and nutrition applications to develop and manufacture superior quality human milk oligosaccharide CARE4U™ 2’-FL,” said Erasmo Schutzer, President of Lonza’s Consumer Health Division.
Naturally present in human milk, human milk oligosaccharides (HMOs) have been shown to support digestive, immune and cognitive development in infants by modifying the gut microbiota. Infant formula attempts to mimic the nutritional composition of breast milk as closely as possible, and clinical studies have shown that CARE4U™ 2’-FL can mimic some of the health-promoting effects of HMOs. CARE4U™ 2’-FL is produced by microbial fermentation and the final product contains more than 98 percent 2’-fucosyllactose, the most abundant of the more than 130 oligosaccharides in human milk. This makes CARE4U™ 2’-FL one of the purest human milk oligosaccharide products on the market today. Superior powder properties (high purity and density) of CARE4U™ 2’-FL make it easy to use in infant formula and dietary supplements.
With ever increasing world population there is likely to be an increased and growing demand for infant nutrition products including HMOs for infant formula. Through the agreement with Lonza, DuPont Nutrition & Health will obtain a significant volume and high quality, reliable supply chain to be able to provide functional human milk oligosaccharide 2-fucosyllactose (2’-FL) for these growing global markets.
For more information about CARE4U™ 2’-FL, visit https://www.dupontnutritionandhealth.com/product-range/hmos.html